肝脏 ›› 2020, Vol. 25 ›› Issue (10): 1076-1078.

• 肝癌 • 上一篇    下一篇

螺旋断层放疗技术在肝细胞癌立体定向放疗中的应用价值

薛健, 陈禄, 王睿, 唐晨虎   

  1. 210014 南京中医药大学附属南京市中西医结合医院放射科(薛健,陈禄,唐晨虎),骨科(王睿);
  • 收稿日期:2019-08-25 出版日期:2020-10-31 发布日期:2020-12-18
  • 通讯作者: 唐晨虎,Email:787232846@qq.com

Application value of helical tomography in SBRT therapy for hepatocellular carcinoma

XUE Jian, CHEN Lu, WANG Rui, TANG Chen-hu   

  1. Department of Radiology, Nanjing Integrated Chinese and Western Medicine Hospital Affiliated to Nanjing University of traditional Chinese Medicine, Jiangsu 210014, China
  • Received:2019-08-25 Online:2020-10-31 Published:2020-12-18
  • Contact: TANG Chen-hu,Email:787232846@qq.com

摘要: 目的 研究螺旋断层放疗(HT)技术在肝细胞癌立体定向放疗(SBRT)治疗中的应用价值。方法 以92例肝细胞癌患者为研究对象,按抽签随机方法分为两组,各46例,其中观察组采用HT技术行SBRT,对照组行射波刀SBRT。分析两组近期疗效,比较治疗前及治疗后4周时血清AST、ALT、胆红素、白蛋白水平,观察不良反应发生情况及随访结果。结果 观察组总有效率为91.30%,对照组为93.48%,差异无统计学意义(P>0.05)。观察组治疗后4周血清AST、ALT、胆红素、白蛋白分别为(53.52±14.85)U/L、(44.96±12.95)U/L、(10.98±3.45)μmol/L、(37.02±3.70)g/L,治疗前分别为(51.78±13.30)U/L、(42.36±11.37)U/L、(10.63±3.37)μmol/L、(37.67±3.85)g/L;对照组治疗后分别为(54.05±15.47)U/L、(45.67±14.75)U/L、(11.67±3.20)μmol/L、(36.42±4.51)g/L,比较差异均无统计学意义(均P>0.05)。观察组不良反应发生率、2年累积生存率分别为21.74%、78.26%,对照组分别为32.61%、89.13%,差异均无统计学意义(P>0.05)。结论 基于HT技术的SBRT对肝细胞癌近远期疗效与射波刀SBRT疗效相近,且安全性较好。

关键词: 螺旋断层放疗, 肝细胞癌, 立体定向放疗

Abstract: Objective To study the application value of helical tomotherapy (HT) in stereotactic body radiotherapy (SBRT) for hepatocellular carcinoma (HCC). Methods A total of 92 patients with HCC admitted to our hospital were divided into 2 groups randomly, 46 cases in each group. The observation group was treated with SBRT by HT, while the control group was treated with SBRT by CyberKnife. The serum levels of aspartate aminotransferase, alanine aminotransferase, bilirubin and albumin were compared pretherapy and 4 weeks after treatment between the 2 groups. The occurrence of adverse reactions and follow-up results were analyzed. Results The total effective rate was 91.30% in the observation group and 93.48% in the control group, with no significant difference (P>0.05). Serum aspartate aminotransferase, alanine aminotransferase, bilirubin and albumin in the observation group were (53.52 ± 14.85) U/L, (44.96 ± 12.95) U/L, (10.98 ± 3.45) μmol/L and (37.02 ± 3.70) g/L 4 weeks after treatment, (51.78 ± 13.30) U/L, (42.36 ± 11.37) U/L, (10.63 ± 3.37) μmol/L and (37.67 ± 3.85) g/L before treatment, respectively. There was no significant difference in the observation before and after treatment (P>0.05). Serum aspartate aminotransferase, alanine aminotransferase, bilirubin and albumin in the control group were (54.05±15.47) U/L, (45.67±14.75) U/L, (11.67±3.20) μmol/L and (36.42±4.51) g/L after treatment. There was no significant difference between the 2 groups after treatment (P>0.05). The incidence of adverse reactions and 2-year cumulative survival rate were 21.74% and 78.26% in the observation group, 32.61% and 89.13% in the control group, respectively, with no significant difference (P>0.05). Conclusion SBRT applied by HT has similar short-term and long-term efficacy with SBRT applied by CyberKnife, and it is safe.

Key words: Helical tomotherapy, Hepatocellular carcinoma, Stereotactic body radiation therapy